Management of Acute Hypertensive Response in Intracerebral Hemorrhage Patients After ATACH-2 Trial.

Abstract

Acute hypertensive response is elevation of systolic blood pressure (SBP) in the first 24 h after symptom onset which is highly prevalent in patients with intracerebral hemorrhage (ICH). Observational studies suggested association between acute hypertensive response and hematoma expansion, peri-hematoma edema and death and disability, and possible reduction in these adverse outcomes with treatment of acute hypertensive response. Recent clinical trials have focused on determining the clinical efficacy of early intensive SBP reduction in ICH patients. The Antihypertensive Treatment of Acute Cerebral Hemorrhage (ATACH-2) trial was the latest phase 3 randomized controlled multicenter clinical trial aimed to study the efficacy of early intensive reduction of SBP in ICH patients. In this review article, we summarize the results of recent clinical trials, treatment principles based on the latest guidelines, and the anticipated interpretation and incorporation of ATACH-2 trial results in clinical practice.

• Authors: Shahram Majidi, Jose I Suarez, Adnan I Qureshi
• Journal: Neurocritical care (Neurocrit Care) Vol. 27 Issue 2 Pg. 249-258 (Oct 2017) ISSN: 1556-0961 [Electronic] United States
• PMID: 28004328 (Publication Type: Journal Article, Review)

Topics

• Cerebral Hemorrhage (complications, therapy)
• Clinical Trials, Phase III as Topic
• Humans
• Hypertension (etiology, therapy)
• Multicenter Studies as Topic
• Outcome and Process Assessment, Health Care
• Randomized Controlled Trials as Topic